Paul Weiss

Dr. Weiss has been a member of the FluGen board since 2015. He joined Venture Investors in 2006 as a Managing Director and focuses on making Healthcare investments. Dr. Weiss has over 20 years of operating experience in the biotech and pharmaceutical industries. He previously was President of the Gala Biotech business unit of Cardinal Health (now part of Catalent). Before joining Gala, he served as the VP of Business Development for 3-Dimensional Pharmaceuticals, a biotechnology company that completed its IPO during his tenure and was subsequently acquired by Johnson & Johnson. Earlier in his career, Dr. Weiss worked as Director of Licensing for Wyeth-Ayerst Pharmaceuticals, (now Pfizer). He also served as Director of Business Development and Research for Scientific Protein Labs, then a division of American Home Products, and Director of Operations for Columbia Research Labs, which focused on women’s health, and is now part of Catalent.

In addition to FluGen, Dr. Weiss is currently a member of the Board of Directors for Invenra, and Madison Vaccines Incorporated. Dr. Weiss also serves on the Board of Directors for TamirBio (formerly Alfacell Corporation (NASDAQ: ACEL), and on the Board of Visitors for the Waisman Center and Waisman Biomanufacturing at the University of Wisconsin-Madison. Dr. Weiss was previously on the boards of Akebia Therapeutics (NASDAQ: AKBA), Neurovance (sold to Otsuka Pharmaceuticals), and Aerpio Pharmaceuticals (NASDAQ: ARPO).

Dr. Weiss received a B.S. in Biochemistry with honors from Carleton University in Ottawa, Ontario, Canada, a Ph.D. in Biochemistry and an M.B.A. from the University of Wisconsin-Madison, where he also worked as a postdoctoral research associate.